A phases I/II of FLD-103, an intralesional treatment against basal cell carcinoma (BCC)
Latest Information Update: 07 Nov 2024
At a glance
- Drugs FLD 103 (Primary)
- Indications Basal cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Feldan Therapeutics
Most Recent Events
- 31 Oct 2024 Status changed from planning to recruiting, according to a Feldan therapeutic media release.
- 31 Oct 2024 According to a Feldan therapeutic media release, company announced its first patient being dosed in Phase 1/2a clinical study of Lead development candidate FLD-103; an intralesional injection intended to provide an alternative to surgery to patients diagnosed with basal cell carcinoma (BCC).
- 04 Sep 2024 According to a Feldan therapeutic media release, the company received a US$ 21 million Series B round co-led by Genesys Capital (Genesys) and Fonds de solidarite FTQ (Fonds) proceeds from this trial will be used to complete this trial.